@morley
yes, that's a good point (regarding the discount rate used to value biological assets).
At the same time, I would be surprised that the market values ATP based on a P/B of 1 x, if they are able to keep their existing level of free cash flow.
If ATP is valued at its book value, it still corresponds to a free cash flow yield of around 29 %.
Ann: 31 December 2021 Interim Financial Report, page-24
Add ATP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.86M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.0¢ | $42.99K | 380.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 58000 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 423831 | 5 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| ATP (ASX) Chart |